These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 23808297)

  • 1. [Metabolic correction of dyslipidemia in patients with nonalcoholic fatty liver disease as a new therapy policy].
    Stel'makh VV; Kozlov VK
    Ter Arkh; 2013; 85(4):71-6. PubMed ID: 23808297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pathogenetic therapy of metabolic syndrome at the stage of visceral lesions].
    Stel'makh VV; Kozlov VK; Radchenko VG; Nekrasova AS
    Klin Med (Mosk); 2012; 90(6):61-5. PubMed ID: 22997724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Evaluation of the efficiency of hepatoprotective monotherapy using succinic acid and methionine for nonalcoholic fatty liver disease at the stage of steatohepatitis].
    Semiserin VA; Karakozov AG; Malkuta MA; Zolotareva LA; Levchenko OB; Kalyagin IE; Eremin MN
    Ter Arkh; 2016; 88(2):58-63. PubMed ID: 27030185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [THE USE OF REMAXOL IN THE TREATMENT OF METABOLIC SYNDROME IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS AND DIABETES MELLITUS 2 TYPE].
    Dudorenko SV; Kovalenko AL; Prokopenko SM; Belogurova EV
    Eksp Klin Gastroenterol; 2016; (6):89-94. PubMed ID: 30280846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Non-alcoholic fatty liver disease in dyslipidemia and insulin resistance: similarities and differences; differential approach to therapy].
    Lazebnik LB; Zvenigorodskaia LA; Egorova EG; Mel'nikova NV; Khomeriki SG
    Eksp Klin Gastroenterol; 2009; (8):4-11. PubMed ID: 20469672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study.
    Athyros VG; Mikhailidis DP; Didangelos TP; Giouleme OI; Liberopoulos EN; Karagiannis A; Kakafika AI; Tziomalos K; Burroughs AK; Elisaf MS
    Curr Med Res Opin; 2006 May; 22(5):873-83. PubMed ID: 16709309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relationship between insulin resistance, metabolic syndrome and nonalcoholic fatty liver disease in non-obese non-diabetic Turkish individuals: A pilot study.
    Erkan G; Sayın I; Polat FB; Çorakçı A; Ataç GK; Değertekin H
    Turk J Gastroenterol; 2014 Dec; 25 Suppl 1():63-8. PubMed ID: 25910371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effectiveness of the hepatoprotective activity of reamberine, remaxol, and ademethionine and risk assessment in their use in patients with respiratory tuberculosis and drug-induced liver injury].
    Sukhanov DS
    Ter Arkh; 2012; 84(11):26-9. PubMed ID: 23252243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property.
    Hyogo H; Yamagishi S; Maeda S; Kimura Y; Ishitobi T; Chayama K
    Dig Liver Dis; 2012 Jun; 44(6):492-6. PubMed ID: 22265683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Advisability of using probiotics in the treatment of atherogenic dyslipidemia].
    Zvenigorodskaia LA; Cherkashova EA; Samsonova NG; Nilova TV; Sil'verstova SIu
    Eksp Klin Gastroenterol; 2011; (2):37-43. PubMed ID: 21563361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparative evaluation of clinical efficacy of drugs remaxol and ademetionine in patients with acute ethanol poisoning complicated by the toxic damage of the liver].
    Shilov VV; Shikalova IA; Batotsyrenov BV; Andrianov AIu; Vasil'ev SA; Loladze AT
    Georgian Med News; 2012 Apr; (205):38-43. PubMed ID: 22665730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Correction of metabolic disorders during treatment of alcohol-induced liver injuries in patients with acute alcoholic intoxication].
    Shilov VV; Shikalova IA; Vasil'ev SA; Batotsyrenov BV; Andrianov AIu
    Klin Med (Mosk); 2013; 91(2):45-8. PubMed ID: 23718065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic Steatosis and Insulin Resistance, But Not Steatohepatitis, Promote Atherogenic Dyslipidemia in NAFLD.
    Bril F; Sninsky JJ; Baca AM; Superko HR; Portillo Sanchez P; Biernacki D; Maximos M; Lomonaco R; Orsak B; Suman A; Weber MH; McPhaul MJ; Cusi K
    J Clin Endocrinol Metab; 2016 Feb; 101(2):644-52. PubMed ID: 26672634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia.
    Hyogo H; Tazuma S; Arihiro K; Iwamoto K; Nabeshima Y; Inoue M; Ishitobi T; Nonaka M; Chayama K
    Metabolism; 2008 Dec; 57(12):1711-8. PubMed ID: 19013295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome.
    Deushi M; Nomura M; Kawakami A; Haraguchi M; Ito M; Okazaki M; Ishii H; Yoshida M
    FEBS Lett; 2007 Dec; 581(29):5664-70. PubMed ID: 18022391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Efficiency of ursodeoxycholic acid therapy in non-alcoholic fatty liver disease associated with metabolic syndrome].
    Avalueva EB; Tkachenko EI; Skazyvaeva EV; Ivanov SV; Orishak EA; Lapinskiĭ IV
    Eksp Klin Gastroenterol; 2013; (11):26-30. PubMed ID: 24933975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antioxidant properties of remaxol, reamberin, and ademetionine in patients with drug-induced liver injury on the background of antituberculous therapy].
    Sukhanov DS
    Eksp Klin Farmakol; 2013; 76(4):45-8. PubMed ID: 23762990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-3 polyunsaturated fatty acids in the treatment of atherogenic dyslipidemia.
    Vecka M; Dušejovská M; Stankova B; Zeman M; Vavrova L; Kodydkova J; Slaby A; Zak A
    Neuro Endocrinol Lett; 2012; 33 Suppl 2():87-92. PubMed ID: 23183517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of fenofibrate in clinical practice.
    Zambon A; Cusi K
    Diab Vasc Dis Res; 2007 Sep; 4 Suppl 3():S15-20. PubMed ID: 17935056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective effect of clove oil and eugenol microemulsions on fatty liver and dyslipidemia as components of metabolic syndrome.
    Al-Okbi SY; Mohamed DA; Hamed TE; Edris AE
    J Med Food; 2014 Jul; 17(7):764-71. PubMed ID: 24611461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.